Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Brendan P. Eckelman, Anthony W. Tolcher et al.|Clinical Cancer Research|2023Cited by 40
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumoursBreelyn A. Wilky, Nilofer S. Azad|British Journal of Cancer|2014Cited by 37